AGMB 129
Alternative Names: AGMB-129; ORG-129Latest Information Update: 21 Aug 2025
At a glance
- Originator Origo Biopharma
- Developer AgomAb Therapeutics
- Class Anti-inflammatories; Antifibrotics; Small molecules
- Mechanism of Action Transforming growth factor beta type I receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Crohn's disease
Most Recent Events
- 12 Aug 2025 Agomab Therapeutics plans a phase I trial for Crohn's disease (In volunteers) in August 2025 (PO (NCT07118878)
- 06 Aug 2025 Agomab Therapeutics initiates a phase I trial in Crohn's disease (In volunteers) (PO (NCT07118878) (CTIS2025-521705-40-00)
- 06 May 2025 Efficacy, adverse events, pharmacokinetic and pharmacodynamic data from the phase IIa STENOVA trial in Crohn's disease released by AgomAb Therapeutics